{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T23:08:51Z","timestamp":1794092931321,"version":"4.8.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T00:00:00Z","timestamp":1696896000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T00:00:00Z","timestamp":1696896000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["089179"],"award-info":[{"award-number":["089179"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","award":["089179"],"award-info":[{"award-number":["089179"]}],"id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Salary support from the U.S. President\u2019s Malaria Initiative"},{"DOI":"10.13039\/501100003593","name":"National Council for Scientific and Technological Development","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Wellcome Trust Principal Fellow","award":["093956\/Z\/10\/C"],"award-info":[{"award-number":["093956\/Z\/10\/C"]}]},{"name":"Australian National Health and Medical Research Council","award":["2008501"],"award-info":[{"award-number":["2008501"]}]},{"name":"Australian National Health and Medical Research Council","award":["1196068"],"award-info":[{"award-number":["1196068"]}]},{"name":"Australian National Health and Medical Research Council","award":["1194702"],"award-info":[{"award-number":["1194702"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Malar J"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Imperfect adherence is a major barrier to effective primaquine radical cure of <jats:italic>Plasmodium vivax<\/jats:italic>. This study investigated the effect of reduced adherence on the risk of <jats:italic>P. vivax<\/jats:italic> recurrence.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Efficacy studies of patients with uncomplicated <jats:italic>P. vivax<\/jats:italic> malaria, including a treatment arm with daily primaquine, published between January 1999 and March 2020 were identified. Individual patient data from eligible studies were pooled using standardized methodology. Adherence to primaquine was inferred from i) the percentage of supervised doses and ii) the total mg\/kg dose received compared to the target total mg\/kg dose per protocol. The effect of adherence to primaquine on the incidence of <jats:italic>P. vivax<\/jats:italic> recurrence between days 7 and 90 was investigated by Cox regression analysis.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Of 82 eligible studies, 32 were available including 6917 patients from 18 countries. For adherence assessed by percentage of supervised primaquine, 2790 patients (40.3%) had poor adherence (\u2264\u200950%) and 4127 (59.7%) had complete adherence. The risk of recurrence by day 90 was 14.0% [95% confidence interval: 12.1\u201316.1] in patients with poor adherence compared to 5.8% [5.0\u20136.7] following full adherence; p\u2009=\u20090.014. After controlling for age, sex, baseline parasitaemia, and total primaquine dose per protocol, the rate of the first recurrence was higher following poor adherence compared to patients with full adherence (adjusted hazard ratio (AHR)\u2009=\u20092.3 [1.8\u20132.9]). When adherence was quantified by total mg\/kg dose received among 3706 patients, 347 (9.4%) had poor adherence, 88 (2.4%) had moderate adherence, and 3271 (88.2%) had complete adherence to treatment. The risks of recurrence by day 90 were 8.2% [4.3\u201315.2] in patients with poor adherence and 4.9% [4.1\u20135.8] in patients with full adherence; p\u2009&lt;\u20090.001.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Reduced adherence, including less supervision, increases the risk of vivax recurrence.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12936-023-04725-w","type":"journal-article","created":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T11:03:11Z","timestamp":1696935791000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":41,"title":["Effect of adherence to primaquine on the risk of Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis"],"prefix":"10.1186","volume":"22","author":[{"given":"Parinaz","family":"Mehdipour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megha","family":"Rajasekhar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saber","family":"Dini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Zaloumis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tesfay","family":"Abreha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ishag","family":"Adam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ghulam Rahim","family":"Awab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Kevin","family":"Baird","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larissa W.","family":"Brasil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy S.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liwang","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9","family":"Daher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margarete","family":"do Socorro M Gomes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lilia","family":"Gonzalez\u2011Ceron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimee","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harin","family":"Karunajeewa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus V. G.","family":"Lacerda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Ladeia-Andrade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toby","family":"Leslie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedikt","family":"Ley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kartini","family":"Lidia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Llanos-Cuentas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rhea J.","family":"Longley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wuelton Marcelo","family":"Monteiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dhelio B.","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Komal Raj","family":"Rijal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavitha","family":"Saravu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge","family":"Sutanto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter R. J.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pham Vinh","family":"Thanh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamala","family":"Thriemer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 Luiz F.","family":"Vieira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas J.","family":"White","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lina M.","family":"Zuluaga-Idarraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe J.","family":"Guerin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ric N.","family":"Price","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Simpson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Commons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the WWARN Vivax Adherence Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bipin","family":"Adhikari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Shafiul","family":"Alam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashenafi","family":"Assefa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah C.","family":"Boyd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nguyen Hoang","family":"Chau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas P. J.","family":"Day","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamiru Shibiru","family":"Degaga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjen M.","family":"Dondorp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Erhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcelo U.","family":"Ferreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash","family":"Ghimire","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin A.","family":"Green","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wasif Ali","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin C. K. W.","family":"Koh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asrat Hailu","family":"Mekuria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivo","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Nader","family":"Naadim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erni J.","family":"Nelwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francois","family":"Nosten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayodhia Pitaloka","family":"Pasaribu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sasithon","family":"Pukrittayakamee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Rowland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jetsumon","family":"Sattabongkot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kasia","family":"Stepniewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilherme","family":"Suarez\u2011Kurtz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorenz von","family":"Seidlein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles J.","family":"Woodrow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adugna","family":"Woyessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,10]]},"reference":[{"key":"4725_CR1","volume-title":"Global Malaria Programme. Global technical strategy for malaria, 2016\u20132030","author":"WHO","year":"2015","unstructured":"WHO. Global Malaria Programme. Global technical strategy for malaria, 2016\u20132030. Geneva: World Health Organization; 2015."},{"key":"4725_CR2","volume-title":"World Malaria Report Geneva","author":"WHO","year":"2022","unstructured":"WHO. World Malaria Report Geneva. Geneva: World Health Organization; 2022."},{"key":"4725_CR3","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/s41467-017-01352-3","volume":"8","author":"JD Challenger","year":"2017","unstructured":"Challenger JD, Bruxvoort K, Ghani AC, Okell LC. Assessing the impact of imperfect adherence to artemether-lumefantrine on malaria treatment outcomes using within-host modelling. Nat Commun. 2017;8:1373.","journal-title":"Nat Commun"},{"key":"4725_CR4","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0140-6736(19)31096-7","volume":"394","author":"KE Battle","year":"2019","unstructured":"Battle KE, Lucas TCD, Nguyen M, Howes RE, Nandi AK, Twohig KA, et al. Mapping the global endemicity and clinical burden of Plasmodium vivax, 2000\u201317: a spatial and temporal modelling study. Lancet. 2019;394:332\u201343.","journal-title":"Lancet"},{"key":"4725_CR5","doi-asserted-by":"crossref","first-page":"79","DOI":"10.4269\/ajtmh.2007.77.79","volume":"77","author":"RN Price","year":"2007","unstructured":"Price RN, Tjitra E, Guerra CA, Yeung S, White NJ, Anstey NM. Vivax malaria: neglected and not benign. Am J Trop Med Hyg. 2007;77:79\u201387.","journal-title":"Am J Trop Med Hyg"},{"key":"4725_CR6","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/S1473-3099(21)00358-3","volume":"22","author":"JR Poespoprodjo","year":"2022","unstructured":"Poespoprodjo JR, Burdam FH, Candrawati F, Ley B, Meagher N, Kenangalem E, et al. Supervised versus unsupervised primaquine radical cure for the treatment of falciparum and vivax malaria in Papua, Indonesia: a cluster-randomised, controlled, open-label superiority trial. Lancet Infect Dis. 2022;22:367\u201376.","journal-title":"Lancet Infect Dis"},{"key":"4725_CR7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002379","volume":"14","author":"NM Douglas","year":"2017","unstructured":"Douglas NM, Poespoprodjo JR, Patriani D, Malloy MJ, Kenangalem E, Sugiarto P, et al. Unsupervised primaquine for the treatment of Plasmodium vivax malaria relapses in southern Papua: a hospital-based cohort study. PLoS Med. 2017;14: e1002379.","journal-title":"PLoS Med"},{"key":"4725_CR8","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1186\/s12936-021-03793-0","volume":"20","author":"KMO Dinelly","year":"2021","unstructured":"Dinelly KMO, Vitor-Silva S, Brito-Sousa JD, Sampaio VS, Silva MGO, Siqueira AM, et al. Evaluation of the effect of supervised anti-malarial treatment on recurrences of Plasmodium vivax malaria. Malar J. 2021;20:266.","journal-title":"Malar J"},{"key":"4725_CR9","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S1473-3099(18)30348-7","volume":"18","author":"RJ Commons","year":"2018","unstructured":"Commons RJ, Simpson JA, Thriemer K, Humphreys GS, Abreha T, Alemu SG, et al. The effect of chloroquine dose and primaquine on Plasmodium vivax recurrence: a WorldWide antimalarial resistance network systematic review and individual patient pooled meta-analysis. Lancet Infect Dis. 2018;18:1025\u201334.","journal-title":"Lancet Infect Dis"},{"key":"4725_CR10","first-page":"181","volume":"7","author":"RJ Commons","year":"2017","unstructured":"Commons RJ, Thriemer K, Humphreys G, Suay I, Sibley CH, Guerin PJ, et al. The Vivax Surveyor: online mapping database for Plasmodium vivax clinical trials. Int J Parasitol: Drugs Drug Resist. 2017;7:181\u201390.","journal-title":"Int J Parasitol: Drugs Drug Resist"},{"key":"4725_CR11","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372: n160.","journal-title":"BMJ"},{"key":"4725_CR12","unstructured":"Clinical Module: Data Management and Statistical Analysis Plan Version 1.2 Clinical Module WorldWide Antimalarial Resistance Network (WWARN). Accessed 27 Aug 2019."},{"key":"4725_CR13","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0001814","volume":"6","author":"PW Gething","year":"2012","unstructured":"Gething PW, Elyazar IRF, Moyes CL, Smith DL, Battle KE, Guerra CA, et al. A long neglected world malaria map: Plasmodium vivax endemicity in 2010. PLoS Negl Trop Dis. 2012;6: e1814.","journal-title":"PLoS Negl Trop Dis"},{"key":"4725_CR14","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/1475-2875-13-144","volume":"13","author":"KE Battle","year":"2014","unstructured":"Battle KE, Karhunen MS, Bhatt S, Gething PW, Howes RE, Golding N, et al. Geographical variation in Plasmodium vivax relapse. Malar J. 2014;13:144.","journal-title":"Malar J"},{"key":"4725_CR15","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S1473-3099(18)30596-6","volume":"19","author":"RJ Commons","year":"2019","unstructured":"Commons RJ, Simpson JA, Thriemer K, Hossain MS, Douglas NM, Humphreys GS, et al. Risk of Plasmodium vivax parasitaemia after Plasmodium falciparum infection: a systematic review and meta-analysis. Lancet Infect Dis. 2019;19:91\u2013101.","journal-title":"Lancet Infect Dis"},{"key":"4725_CR16","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/1475-2875-11-280","volume":"11","author":"GK John","year":"2012","unstructured":"John GK, Douglas NM, Von Seidlein L, Nosten F, Baird JK, White NJ, et al. Primaquine radical cure of Plasmodium vivax: a critical review of the literature. Malar J. 2012;11:280.","journal-title":"Malar J"},{"key":"4725_CR17","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1186\/1475-2875-7-149","volume":"7","author":"SJ Lee","year":"2008","unstructured":"Lee SJ, Stepniewska K, Anstey N, Ashley E, Barnes K, Binh TQ, et al. The relationship between the haemoglobin concentration and the haematocrit in Plasmodium falciparum malaria. Malar J. 2008;7:149.","journal-title":"Malar J"},{"key":"4725_CR18","unstructured":"Vivax Adherence Study Group statistical analysis plan. Worldwide Antimalarial Resistance Network. https:\/\/www.wwarn.org\/tools-resources\/vivax-adherence-study-group-statistical-analysis-plan Accessed 7 Feb 2022."},{"key":"4725_CR19","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1086\/512677","volume":"44","author":"AR Hasugian","year":"2007","unstructured":"Hasugian AR, Purba HL, Kenangalem E, Wuwung RM, Ebsworth EP, Maristela R, et al. Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. Clin Infect Dis. 2007;44:1067\u201374.","journal-title":"Clin Infect Dis"},{"key":"4725_CR20","volume":"3","author":"T Leslie","year":"2008","unstructured":"Leslie T, Mayan I, Mohammed N, Erasmus P, Kolaczinski J, Whitty CJ, et al. A randomised trial of an eight-week, once weekly primaquine regimen to prevent relapse of Plasmodium vivax in Northwest Frontier Province. Pakistan PLoS One. 2008;3: e2861.","journal-title":"Pakistan PLoS One"},{"key":"4725_CR21","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1186\/1475-2875-11-404","volume":"11","author":"TM Abdallah","year":"2012","unstructured":"Abdallah TM, Ali AA, Bakri M, Gasim GI, Musa IR, Adam I. Efficacy of artemether-lumefantrine as a treatment for uncomplicated Plasmodium vivax malaria in eastern Sudan. Malar J. 2012;11:404.","journal-title":"Malar J"},{"issue":"1","key":"4725_CR22","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1128\/AAC.02279-12","volume":"58","author":"MM Marques","year":"2014","unstructured":"Marques MM, Costa MR, Santana Filho FS, Vieira JL, Nascimento MT, Brasil LW, et al. Plasmodium vivax chloroquine resistance and anemia in the western Brazilian Amazon. Antimicrob Agents Chemother. 2014;58(1):342\u20137. https:\/\/doi.org\/10.1128\/AAC.02279-12.","journal-title":"Antimicrob Agents Chemother"},{"key":"4725_CR23","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1186\/s12936-015-0925-7","volume":"14","author":"S Gomes Mdo","year":"2015","unstructured":"Gomes Mdo S, Vieira JL, Machado RL, Nacher M, Stefani A, Musset L, et al. Efficacy in the treatment of malaria by Plasmodium vivax in Oiapoque, Brazil, on the border with French Guiana: the importance of control over external factors. Malar J. 2015;14:402.","journal-title":"Malar J"},{"key":"4725_CR24","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1186\/s12936-015-0938-2","volume":"14","author":"L Gonzalez-Ceron","year":"2015","unstructured":"Gonzalez-Ceron L, Rodriguez MH, Sandoval MA, Santillan F, Galindo-Virgen S, Betanzos AF, et al. Effectiveness of combined chloroquine and primaquine treatment in 14 days versus intermittent single dose regimen, in an open, non-randomized, clinical trial, to eliminate Plasmodium vivax in southern Mexico. Malar J. 2015;14:426.","journal-title":"Malar J"},{"issue":"2","key":"4725_CR25","first-page":"247","volume":"31","author":"K Lidia","year":"2015","unstructured":"Lidia K, Dwiprahasto I, Kristin E. Therapeutic effects of dyhidroartemisinin piperaquine versus chloroquine for uncomplicated Vivax Malaria in Kupang, East Nusa Tenggara, Indonesia. Int J Pharm Sci Rev Res. 2015;31(2):247\u201351.","journal-title":"Int J Pharm Sci Rev Res"},{"key":"4725_CR26","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1186\/s12916-015-0535-9","volume":"13","author":"EJ Nelwan","year":"2015","unstructured":"Nelwan EJ, Ekawati LL, Tjahjono B, Setiabudy R, Sutanto I, Chand K, et al. Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia. BMC Med. 2015;13:294.","journal-title":"BMC Med"},{"key":"4725_CR27","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1186\/s12936-015-0824-y","volume":"14","author":"K Rishikesh","year":"2015","unstructured":"Rishikesh K, Kamath A, Hande MH, Vidyasagar S, Acharya RV, Acharya V, et al. Therapeutic assessment of chloroquine-primaquine combined regimen in adult cohort of Plasmodium vivax malaria from a tertiary care hospital in southwestern India. Malar J. 2015;14:310.","journal-title":"Malar J"},{"key":"4725_CR28","doi-asserted-by":"crossref","first-page":"7411","DOI":"10.1128\/AAC.00791-15","volume":"59","author":"PV Thanh","year":"2015","unstructured":"Thanh PV, Hong NV, Van NV, Louisa M, Baird K, Xa NX, et al. Confirmed Plasmodium vivax resistance to chloroquine in Central Vietnam. Antimicrob Agents Chemother. 2015;59:7411\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"4725_CR29","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1128\/AAC.04270-14","volume":"59","author":"L Yuan","year":"2015","unstructured":"Yuan L, Wang Y, Parker DM, Gupta B, Yang Z, Liu H, et al. Therapeutic responses of Plasmodium vivax malaria to chloroquine and primaquine treatment in northeastern Myanmar. Antimicrob Agents Chemother. 2015;59:1230\u20135.","journal-title":"Antimicrob Agents Chemother"},{"key":"4725_CR30","volume":"11","author":"B Ley","year":"2016","unstructured":"Ley B, Alam MS, Thriemer K, Hossain MS, Kibria MG, Auburn S, et al. G6PD deficiency and antimalarial efficacy for uncomplicated malaria in Bangladesh: a prospective observational study. PLoS ONE. 2016;11: e0154015.","journal-title":"PLoS ONE"},{"key":"4725_CR31","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.4269\/ajtmh.16-0410","volume":"95","author":"RJ Longley","year":"2016","unstructured":"Longley RJ, Sripoorote P, Chobson P, Saeseu T, Sukasem C, Phuanukoonnon S, et al. High efficacy of primaquine treatment for Plasmodium vivax in Western Thailand. Am J Trop Med Hyg. 2016;95:1086\u20139.","journal-title":"Am J Trop Med Hyg"},{"key":"4725_CR32","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1186\/s12936-016-1530-0","volume":"15","author":"D Pereira","year":"2016","unstructured":"Pereira D, Daher A, Zanini G, Maia I, Fonseca L, Pitta L, et al. Safety, efficacy and pharmacokinetic evaluations of a new coated chloroquine tablet in a single-arm open-label non-comparative trial in Brazil: a step towards a user-friendly malaria vivax treatment. Malar J. 2016;15:477.","journal-title":"Malar J"},{"key":"4725_CR33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157666","volume":"11","author":"K Saravu","year":"2016","unstructured":"Saravu K, Kumar R, Ashok H, Kundapura P, Kamath V, Kamath A, et al. Therapeutic assessment of chloroquine-primaquine combined regimen in adult cohort of Plasmodium vivax malaria from primary care centres in Southwestern India. PLoS ONE. 2016;11: e0157666.","journal-title":"PLoS ONE"},{"key":"4725_CR34","doi-asserted-by":"crossref","first-page":"4610","DOI":"10.1128\/AAC.00186-16","volume":"60","author":"L Zuluaga-Idarraga","year":"2016","unstructured":"Zuluaga-Idarraga L, Blair S, Akinyi Okoth S, Udhayakumar V, Marcet PL, Escalante AA, et al. Prospective study of Plasmodium vivax malaria recurrence after radical treatment with a chloroquine-primaquine standard regimen in Turbo. Colombia Antimicrob Agents Chemother. 2016;60:4610\u20139.","journal-title":"Colombia Antimicrob Agents Chemother"},{"key":"4725_CR35","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1002299","volume":"14","author":"T Abreha","year":"2017","unstructured":"Abreha T, Hwang J, Thriemer K, Tadesse Y, Girma S, Melaku Z, et al. Comparison of artemether-lumefantrine and chloroquine with and without primaquine for the treatment of Plasmodium vivax infection in Ethiopia: a randomized controlled trial. PLoS Med. 2017;14: e1002299.","journal-title":"PLoS Med"},{"key":"4725_CR36","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.4269\/ajtmh.17-0290","volume":"97","author":"GR Awab","year":"2017","unstructured":"Awab GR, Imwong M, Bancone G, Jeeyapant A, Day NPJ, White NJ, et al. Chloroquine-primaquine versus chloroquine alone to treat vivax malaria in Afghanistan: an open randomized superiority trial. Am J Trop Med Hyg. 2017;97:1782\u20137.","journal-title":"Am J Trop Med Hyg"},{"key":"4725_CR37","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1186\/s12936-017-2139-7","volume":"17","author":"LW Brasil","year":"2018","unstructured":"Brasil LW, Rodrigues-Soares F, Santoro AB, Almeida ACG, Kuhn A, Ramasawmy R, et al. CYP2D6 activity and the risk of recurrence of Plasmodium vivax malaria in the Brazilian Amazon: a prospective cohort study. Malar J. 2018;17:57.","journal-title":"Malar J"},{"key":"4725_CR38","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1093\/cid\/ciy319","volume":"67","author":"CS Chu","year":"2018","unstructured":"Chu CS, Phyo AP, Lwin KM, Win HH, San T, Aung AA, et al. Comparison of the cumulative efficacy and safety of chloroquine, artesunate, and chloroquine-primaquine in Plasmodium vivax malaria. Clin Infect Dis. 2018;67:1543\u20139.","journal-title":"Clin Infect Dis"},{"key":"4725_CR39","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-018-2192-x","author":"A Daher","year":"2018","unstructured":"Daher A, Pereira D, Lacerda MVG, Alexandre MAA, Nascimento CT, Alves de Lima ESJC, et al. Efficacy and safety of artemisinin-based combination therapy and chloroquine with concomitant primaquine to treat Plasmodium vivax malaria in Brazil: an open label randomized clinical trial. Malar J. 2018. https:\/\/doi.org\/10.1186\/s12936-018-2192-x.","journal-title":"Malar J"},{"key":"4725_CR40","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1186\/s12936-018-2472-5","volume":"17","author":"K Saravu","year":"2018","unstructured":"Saravu K, Tellapragada C, Kulavalli S, Xavier W, Umakanth S, Brahmarouphu G, et al. A pilot randomized controlled trial to compare the effectiveness of two 14-day primaquine regimens for the radical cure of vivax malaria in South India. Malar J. 2018;17:321.","journal-title":"Malar J"},{"key":"4725_CR41","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1093\/cid\/ciy735","volume":"68","author":"CS Chu","year":"2019","unstructured":"Chu CS, Phyo AP, Turner C, Win HH, Poe NP, Yotyingaphiram W, et al. Chloroquine versus dihydroartemisinin-piperaquine with standard high-dose primaquine given either for 7 days or 14 days in Plasmodium vivax malaria. Clin Infect Dis. 2019;68:1311\u20139.","journal-title":"Clin Infect Dis"},{"key":"4725_CR42","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1186\/s12936-019-3072-8","volume":"18","author":"LWP De Sena","year":"2019","unstructured":"De Sena LWP, Mello AGNC, Ferreira MVD, De Ataide MA, Dias RM, Vieira JLF. Doses of chloroquine in the treatment of malaria by Plasmodium vivax in patients between 2 and 14 years of age from the Brazilian Amazon basin. Malar J. 2019;18:439.","journal-title":"Malar J"},{"key":"4725_CR43","doi-asserted-by":"crossref","first-page":"e01965","DOI":"10.1128\/AAC.01965-18","volume":"63","author":"S Ladeia-Andrade","year":"2019","unstructured":"Ladeia-Andrade S, Menezes MJ, de Sousa TN, Silvino ACR, de Carvalho JF, Salla LC, et al. Monitoring the efficacy of chloroquine-primaquine therapy for uncomplicated Plasmodium vivax malaria in the main transmission hot spot of Brazil. Antimicrob Agents Chemother. 2019;63:e01965-e2018.","journal-title":"Antimicrob Agents Chemother"},{"key":"4725_CR44","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa1802537","volume":"380","author":"A Llanos-Cuentas","year":"2019","unstructured":"Llanos-Cuentas A, Lacerda MVG, Hien TT, Velez ID, Namaik-Larp C, Chu CS, et al. Tafenoquine versus primaquine to prevent relapse of Plasmodium vivax malaria. N Engl J Med. 2019;380:229\u201341.","journal-title":"N Engl J Med"},{"key":"4725_CR45","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa1710775","volume":"380","author":"MVG Lacerda","year":"2019","unstructured":"Lacerda MVG, Llanos-Cuentas A, Krudsood S, Lon C, Saunders DL, Mohammed R, et al. Single-dose tafenoquine to prevent relapse of Plasmodium vivax malaria. N Engl J Med. 2019;380:215\u201328.","journal-title":"N Engl J Med"},{"key":"4725_CR46","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1093\/infdis\/jiz126","volume":"220","author":"KR Rijal","year":"2019","unstructured":"Rijal KR, Adhikari B, Ghimire P, Banjara MR, Das Thakur G, Hanboonkunupakarn B, et al. Efficacy of primaquine in preventing short- and long-latency Plasmodium vivax relapses in Nepal. J Infect Dis. 2019;220:448\u201356.","journal-title":"J Infect Dis"},{"key":"4725_CR47","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0140-6736(19)31285-1","volume":"394","author":"WRJ Taylor","year":"2019","unstructured":"Taylor WRJ, Thriemer K, von Seidlein L, Yuentrakul P, Assawariyathipat T, Assefa A, et al. Short-course primaquine for the radical cure of Plasmodium vivax malaria: a multicentre, randomised, placebo-controlled non-inferiority trial. Lancet. 2019;394:929\u201338.","journal-title":"Lancet"},{"key":"4725_CR48","volume":"36","author":"S Xu","year":"2020","unstructured":"Xu S, Zeng W, Ngassa Mbenda HG, Liu H, Chen X, Xiang Z, et al. Efficacy of directly-observed chloroquine-primaquine treatment for uncomplicated acute Plasmodium vivax malaria in northeast Myanmar: a prospective open-label efficacy trial. Travel Med Infect Dis. 2020;36: 101499.","journal-title":"Travel Med Infect Dis"},{"key":"4725_CR49","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S0140-6736(13)62568-4","volume":"383","author":"A Llanos-Cuentas","year":"2014","unstructured":"Llanos-Cuentas A, Lacerda MV, Rueangweerayut R, Krudsood S, Gupta SK, Kochar SK, et al. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study. Lancet. 2014;383:1049\u201358.","journal-title":"Lancet"},{"key":"4725_CR50","volume-title":"Guidelines for the treatment of malaria","author":"WHO","year":"2015","unstructured":"WHO. Guidelines for the treatment of malaria. 3rd ed. Geneva: World Health Organization; 2015.","edition":"3"},{"key":"4725_CR51","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1086\/424663","volume":"39","author":"JK Baird","year":"2004","unstructured":"Baird JK, Hoffman SL. Primaquine therapy for malaria. Clin Infect Dis. 2004;39:1336\u201345.","journal-title":"Clin Infect Dis"},{"key":"4725_CR52","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s12936-018-2380-8","volume":"17","author":"K Thriemer","year":"2018","unstructured":"Thriemer K, Bobogare A, Ley B, Gudo CS, Alam MS, Anstey NM, et al. Quantifying primaquine effectiveness and improving adherence: a round table discussion of the APMEN Vivax Working Group. Malar J. 2018;17:241.","journal-title":"Malar J"},{"key":"4725_CR53","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1186\/1475-2875-9-308","volume":"9","author":"R Takeuchi","year":"2010","unstructured":"Takeuchi R, Lawpoolsri S, Imwong M, Kobayashi J, Kaewkungwal J, Pukrittayakamee S, et al. Directly-observed therapy (DOT) for the radical 14-day primaquine treatment of Plasmodium vivax malaria on the Thai-Myanmar border. Malar J. 2010;9:308.","journal-title":"Malar J"},{"key":"4725_CR54","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/S0035-9203(03)00041-5","volume":"98","author":"T Leslie","year":"2004","unstructured":"Leslie T, Rab MA, Ahmadzai H, Durrani N, Fayaz M, Kolaczinski J, et al. Compliance with 14-day primaquine therapy for radical cure of vivax malaria\u2013a randomized placebo-controlled trial comparing unsupervised with supervised treatment. Trans R Soc Trop Med Hyg. 2004;98:168\u201373.","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"4725_CR55","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S1471-4922(03)00005-9","volume":"19","author":"JK Baird","year":"2003","unstructured":"Baird JK, Rieckmann KH. Can primaquine therapy for vivax malaria be improved? Trends Parasitol. 2003;19:115\u201320.","journal-title":"Trends Parasitol"},{"key":"4725_CR56","doi-asserted-by":"crossref","first-page":"152","DOI":"10.5694\/mja2.50474","volume":"212","author":"RJ Commons","year":"2020","unstructured":"Commons RJ, McCarthy JS, Price RN. Tafenoquine for the radical cure and prevention of malaria: the importance of testing for G6PD deficiency. Med J Aust. 2020;212:152-153.e1.","journal-title":"Med J Aust"},{"key":"4725_CR57","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0084555","volume":"9","author":"K Bruxvoort","year":"2014","unstructured":"Bruxvoort K, Goodman C, Kachur SP, Schellenberg D. How patients take malaria treatment: a systematic review of the literature on adherence to antimalarial drugs. PLoS ONE. 2014;9: e84555.","journal-title":"PLoS ONE"},{"key":"4725_CR58","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1590\/0102-311X00169312","volume":"30","author":"LR Sim\u00f5es","year":"2014","unstructured":"Sim\u00f5es LR, Alves ER, Ribatski-Silva D, Gomes LT, Nery AF, Fontes CJF. Factors associated with recurrent Plasmodium vivax malaria in Porto Velho, Rond\u00f4nia State, Brazil, 2009. Cad Saude Publica. 2014;30:1403\u201317.","journal-title":"Cad Saude Publica"},{"key":"4725_CR59","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.trstmh.2006.06.008","volume":"101","author":"A Ratcliff","year":"2007","unstructured":"Ratcliff A, Siswantoro H, Kenangalem E, Wuwung M, Brockman A, Edstein MD, et al. Therapeutic response of multidrug-resistant Plasmodium falciparum and P. vivax to chloroquine and sulfadoxine-pyrimethamine in southern Papua, Indonesia. Trans R Soc Trop Med Hyg. 2007;101:351\u20139.","journal-title":"Trans R Soc Trop Med Hyg"}],"container-title":["Malaria Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-023-04725-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12936-023-04725-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12936-023-04725-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T12:06:34Z","timestamp":1700222794000},"score":1,"resource":{"primary":{"URL":"https:\/\/malariajournal.biomedcentral.com\/articles\/10.1186\/s12936-023-04725-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,10]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4725"],"URL":"https:\/\/doi.org\/10.1186\/s12936-023-04725-w","relation":{},"ISSN":["1475-2875"],"issn-type":[{"value":"1475-2875","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,10]]},"assertion":[{"value":"24 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data included in this analysis were obtained in accordance with ethical approvals from the location of origin. Data are anonymized and unable to be linked to individuals. Additional review from an ethics committee was not required for the subsequent analysis according to guidelines of the Oxford Central University Research Ethics Committee.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"306"}}